Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024
Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024
Financial Guidance for 2024
2024年的財務指導
On a GAAP basis, we expect total operating expenses in the range of approximately $145 million to $165 million in 2024, which includes non-cash stock-based compensation expense and depreciation and amortization, subject to additional funding.
按公認會計原則計算，我們預計2024年的總運營支出約爲1.45億美元至1.65億美元，其中包括非現金股票薪酬支出以及折舊和攤銷，但須視額外資金而定。
We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, and depreciation and amortization of approximately $7 million, in the range of approximately $125 million to $145 million in 2024, subject to additional funding.
我們預計，非公認會計准則的總運營支出，不包括估計的約1300萬美元的非現金股票薪酬支出，以及約700萬美元的折舊和攤銷，在2024年約1.25億美元至1.45億美元之間，視額外資金而定。
譯文內容由第三人軟體翻譯。